http://www.mda.org/whatsnew/ 2/1/2012 Get the latest research news from the Muscular Dystrophy Association (MDA) en-us http://quest.mda.org/news/podcast-stephen-tapscott-discusses-role-dux4-fshd 2/2/12 An 11½-minute interview with researcher Stephen Tapscott explores recent findings about the molecular basis of facioscapulohumeral MD http://quest.mda.org/news/mda-commits-12-million-nmd-research 2/1/12 MDA has awarded 38 grants totaling more than $12 million to support research into general muscle health and more than 15 neuromuscular diseases in its program. http://alsn.mda.org/news/mda-awards-2-million-als-grants 2/1/12 The grants fund six new ALS projects, each using a different mechanism to uncover the causes of the disease and potential treatments. http://quest.mda.org/news/jacobus-begins-invitation-only-trial-34-dap-lems 1/25/12 Jacobus is inviting 30 selected individuals with Lambert-Eaton myasthenic syndrome to participate in a placebo-controlled trial of 3,4-DAP. http://alsn.mda.org/news/safety-efficacy-in-brainstorm-stem-cell-trial 1/23/12 NurOwn stem cell technology, currently being tested in Israel, appears safe and seems to improve breathing, swallowing and muscle strength. http://quest.mda.org/news/dux4-causes-muscle-mayhem-fshd 1/20/12 New research explains probable ways in which DUX4 protein, if made at the wrong time and in the wrong place, leads to FSH dystrophy http://alsn.mda.org/news/als-biomarkers-study-seeks-250-participants 1/18/12 Researchers are seeking participants for a study to identify accurate biological indicators of ALS onset, progression and response to treatment. http://quest.mda.org/news/mda-funds-utrophin-magnet-dmdbmd 1/17/12 MDA's $1 million grant will help fund the development of TVN-102, which attracts the muscle protein utrophin to the muscle-fiber membrane. http://quest.mda.org/news/immunosuppression-induces-tolerance-enzyme-treatment-pompe-disease 1/16/12 Four children not making any acid maltase enzyme tolerated enzyme replacement therapy when also treated with immunosuppressants. http://quest.mda.org/news/podcast-probes-exon-skipping-dmd 1/11/2012 Molecular geneticist Stephen Wilton discusses his group's development of exon-skipping compounds to restore dystrophin production in Duchenne MD. http://quest.mda.org/news/phase-1-trial-opens-isis-smnrx-children-sma 1/2/2012 Pharmaceuticals will test its experimental antisense drug in 24 children with spinal muscular atrophy at five U.S. centers.